The big plas­ma al­liance spear­head­ed by Take­da and CSL Behring has a big Phase III ver­dict: Adding their hy­per­im­mune in­tra­venous im­munoglob­u­lin prod­uct to Gilead’s remde­sivir does not stall dis­ease pro­gres­sion.

Dubbed H-Ig, the treat­ment was sup­posed to be a high­er grade ver­sion of con­va­les­cent plas­ma, which for­mer Pres­i­dent Don­ald Trump once hailed as a “his­toric break­through.” But it seems to be fol­low­ing plas­ma down the same path to­ward ob­so­les­cence.

Julie Kim

Com­ing a year af­ter the com­pa­nies an­nounced the part­ner­ship — which they called a bold move to find an­swers amid un­cer­tain­ty — the fail­ure would mark an end to their work, which had in­clud­ed man­u­fac­tur­ing the prod­uct at-risk.

“We are es­pe­cial­ly proud that we pooled re­sources, brought our plas­ma ex­per­tise and in­fra­struc­ture to­geth­er at our own cost to ben­e­fit pub­lic health and added to our un­der­stand­ing of a com­plex field,” said Julie Kim, pres­i­dent of Take­da’s plas­ma-de­rived ther­a­pies busi­ness unit. She co-led the ini­tia­tive with Bill Mez­zan­otte, head of R&D at CSL Behring.

Fund­ed by the NIH, the ITAC tri­al had en­rolled 600 adult pa­tients hos­pi­tal­ized for Covid-19 across 11 coun­tries and of­fered them in­ves­ti­ga­tion­al H-Ig plas­ma treat­ments. In ad­di­tion to Take­da and CSL Behring, Emer­gent BioSo­lu­tions and Gri­fols al­so sup­plied some of the clin­i­cal ma­te­r­i­al, which was processed and pu­ri­fied in a way that re­sult­ed in more con­cen­trat­ed neu­tral­iz­ing an­ti­body ac­tiv­i­ty while min­i­miz­ing safe­ty is­sues.

“IgG con­cen­tra­tion and IgG spe­cif­ic to SARS-CoV-2 were in­creased over 10-fold from con­va­les­cent plas­ma to the fi­nal prod­uct,” a group from Gri­fols de­scribed in a re­cent pa­per. “Nor­mal­ized en­zyme-linked im­munosor­bent as­say ac­tiv­i­ty (per mg/ml IgG) was main­tained through­out the process. Pro­tein con­tent in these fi­nal prod­uct batch­es was 100% IgG, con­sist­ing of 98% monomer and dimer forms. Po­ten­tial­ly haz­ardous pro­teins (IgM, IgA, and an­ti-A, an­ti-B, and an­ti-D) were re­duced to min­i­mal lev­els.”

In­ves­ti­ga­tors com­pared the clin­i­cal sta­tus of pa­tients in each group on day 7 of fol­lowup, mea­sur­ing a spec­trum of out­comes from lim­it­ing symp­toms to death. The com­pa­nies didn’t say much be­yond the fact that H-Ig didn’t meet the pri­ma­ry end­point, say­ing they will pub­lish the re­sults lat­er.

The hos­pi­tal­ized pa­tient pop­u­la­tion has been an elu­sive group for an­ti­bod­ies, de­feat­ing a slew of can­di­dates from Eli Lil­ly, Glax­o­SmithK­line/Vir and Brii Bio.

Plas­ma from healthy donors who have re­cov­ered from Covid-19, mean­while, has al­so had trou­ble liv­ing up to ear­ly ex­pec­ta­tions.

The UK’s RE­COV­ERY tri­al stopped re­cruit­ing pa­tients for its con­va­les­cent plas­ma arm af­ter an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee found no sig­nif­i­cant im­prove­ment in mor­tal­i­ty.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

We oppose all attempts to introduce laws that reduce the rights of US citizens to vote or that restrict them from exercising that right. The right to vote is fundamental to democracy. States that have enacted, or are proposing to enact, legislation to restrict voting are undermining our democracy and posing a threat to our nation. As leaders of the life sciences industry, we stand for what we believe is right for our country, our enterprises, our employees and those who benefit from our work. We join the first groups of business leaders who have challenged these laws and will continue to make our collective voices heard on this matter.

Novavax has had a busy month, filled with supply chain issues and manufacturing deals that have affected the rollout of its Covid-19 vaccine. Tuesday, the company announced updates to its leadership team.

CFO Greg Covino will step down from that role after just five months for personal reasons, the release said, but take on a new role as executive advisor. John Trizzino, current chief commercial officer and chief business officer, will take the CFO role over in the interim.

The FDA and CDC have jointly decided to stop administering J&J’s Covid-19 vaccine after reviewing data involving six reported US cases of a rare and severe type of blood clot in individuals after receiving the vaccine.

CDC will convene a meeting of its Advisory Committee on Immunization Practices on Wednesday to further review these cases and assess their potential significance. “FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research and Anne Schuchat, Principal Deputy Director of the CDC, said in a joint statement Tuesday morning.

There’s another unicorn in biotech land, as Benchling and its leading R&D cloud platform pull in a $200 million Series E to help scientists accelerate drug development. In doing so, the company hit a lofty $4 billion valuation — nearly five times what it was worth around this time last year.

Despite the fact that drug development is becoming significantly more complex, the industry continues to run on paper, emails and spreadsheets, co-founder and CEO Sajith Wickramasekara said in a video on Benchling’s website. The MIT grad sought to change that by creating software that allows scientists to better track, model and forecast their work.

Amylyx is one of several companies looking to break through in the tough ALS field, and Wednesday they announced they’re moving forward with regulatory plans.

The Cambridge, MA-based biotech said they’re submitting a marketing application to the EMA for their AMX0035 program by the end of 2021. Wednesday’s news comes a few weeks after they revealed similar plans to move forward with Canadian health regulators by June 30.

Anand Shah has served the American public in a unique way, crisscrossing over the last two administrations between serving as an attending radiation oncologist focused on prostate cancer at NIH, serving as CMO at the Center for Medicare and Medicaid Innovation, and most recently, leading the FDA’s operations on medical and scientific affairs from within the commissioner’s office.

Shah, who stepped down from the FDA in January, caught up with Endpoints News in a phone interview on Tuesday afternoon, offering his thoughts on the agency’s latest decision to pause the J&J vaccinations in the US, and reflecting on his time at an agency during this once-in-a-lifetime pandemic.